Background and Purpose: Our purpose was to assess the presence of lupus anticoagulant and fibrinolytic system abnormalities in young patients with stroke.
Jn a series of stroke registries recently reviewed, 2-7% of brain infarcts in young adults have been attributed to hematological causes. Among these, fibrinolytic system abnormalities are variably reported, and antiphospholipid antibodies and lupus anticoagulant (LA) are the acquired prothrombotic conditions most frequently detected.' LA is an acquired circulating serum gamma globulin not strictly related to systemic lupus erythematosus (SLE) that in vitro prolongs phospholipid-dependent coagulation tests and, paradoxically, is associated with an increased tendency to venous and arterial thromboses. 2 Screening of young stroke patients for LA has yielded widely varying results,134 probably as a result of the different sensitivity and specificity of each laboratory test.5 To further analyze this problem, we studied certain coagulation and fibrinolytic parameters and the presence of LA in young adults who had suffered from ischemic stroke.
Subjects and Methods
From February 1989 to May 1991, 33 consecutive subjects (27 men, six women; aged 23-49 years) with ischemic stroke gave informed consent to participate in the study. We considered that a patient had suffered from ischemic stroke when he or she had had an acute focal neurological deficit lasting >24 hours and the cerebral infarction was confirmed by computed tomog-raphy. Patients aged >50 years with transient ischemic attack and nonischemic brain diseases were excluded.
LA coagulation screening tests, anticardiolipin antibodies (aCL) circulating titer, and coagulation and fibrinolytic patterns were studied at least 3 months after the onset of the ischemic event. Any drug that could affect clotting and the fibrinolytic system or platelet function was discontinued for at least 2 weeks before the study.
The LA study was carried out by performing four different coagulation tests: activated partial thromboplastin time (aPTT), kaolin clotting time, dilute Russel's viper venom time, and dilute aPTT, assessed as previously described.5 Samples yielding abnormal results were reassessed by mixing fresh patient's plasma in a 1:1 ratio with fresh pooled normal plasma, and clotting times were considered abnormal if longer than the mean+2SD of 25 control subjects matched for age and sex. The presence of LA was diagnosed by the abnormality of two or more coagulation screening tests and by the confirmatory test with 0.05 mM phosphatidylserine-phosphatidylcholine liposomes.' To evaluate aCL, the enzyme-linked immunosorbent assay technique validated in an international workshop was used. 6 Results are expressed as the number of standard deviations above the mean in normal human serum (reference value, <3SD).
Prothrombin activity (Baldacci, Pisa, Italy; reference value, 75-120%), fibrinogen studied according to the Clauss method (Immuno, Pisa, Italy; reference value, 180-400 mg/dl), and factor VII activity assessed by use of tissue thromboplastin of rabbit brain origin (Baldacci; reference value, 75-125%) were measured by use of the Schnitger and Gross coagulometer.
The tissue plasminogen activator (t-PA) antigen (Imubind-5-tPA, American Diagnostica) and plasminogen activator inhibitor (PAI) activity (Kabi Diagnos- Coagulation and fibrinolytic parameters of LA(+), LA(-), and control subjects are shown in Table 2 . PAl activity was significantly higher in LA( +) stroke patients (30.9±.-9.5 units/ml) than in LA(-) patients (12.7±+7.1 units/ml) and healthy subjects (9.5±+4 units! ml) (p<0O.OOl). No statistical differences were found between PAT activity levels of LA(-) patients and control subjects ( pletely clarified.2 Recently we suggested that an imbalance between t-PA and its inhibitor PAI could predispose to thrombosis in LA(+) patients.7 This seems to be confirmed by the present investigation, in which t-PA antigen levels were within normal range, whereas PAI activity, a marker of hypercoagulability previously related to venous and arterial thrombosis,10 was significantly higher in LA(+) patients than in LA(-) patients and control subjects.
In conclusion, our study shows that, among young stroke patients, the presence of LA is associated with an imbalance of the fibrinolytic system as a result of the increased levels of circulating PAI activity. The pathophysiological relevance of this association as a thrombotic risk factor in the pathogenesis of stroke in young adults needs to be verified in larger prospective studies.
